List of Abstracts
048
049
050
051
052
053
054
055
056
057
058
059
060
061
062
063
064
065
066
067
068
070
071
073
074
075
076
077
078
079
080
081
082
083
084
085
086
088
089
090
091
092
093
094
095
096
098
099
100
101
102
3
Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis
Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis:
results from VOYAGE 2
Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis
Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
Relationships Between Tildrakizumab Dose, Exposure, Efficacy and Safety in Psoriasis Phase 3 Studies
Long-Term Safety and Efficacy of Adalimumab from the Phase 3 Randomized, Placebo-Controlled Trial in Patients with Nail and Skin
Psoriasis
Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis
Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials
Primary Efficacy and Safety of Adalimumab in Nail Psoriasis From the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled
Trial With Subanalysis in Patients With and Without Psoriatic Arthritis
Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups
Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort
Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis
Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate-
to-Severe Plaque Psoriasis
Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: Results
from the Phase III ORION self-dose study through Week 16
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast
Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance
Disease Severity and Efficacy Insights: Patient-Level PASI Scores in Tildrakizumab Psoriasis Trials
Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab
Statistic review of psoriasis systematic therapies in North Greece
Pharmakovigilance of systemic antipsoritic drugs: an update from routine care
The Impact of Patient Requests on Psoriatic Arthritis Treatment
Epidemiology
The Risk Of KC In Psoriasis Patients Receiving Biologics Compared To Conventional Systemic Therapies
Patient perceptions of psoriasis severity in Sweden, Norway, and Denmark
Patient expectations and satisfaction in psoriasis treatment: A survey from Europe and Canada
Socioeconomic determinants of paediatric psoriasis
Obesity and the risk of psoriasis: A Korean nationwide, population-based study
Clinical characterization of Psoriatic Arthritis in a multidisciplinary care model of patients with Psoriasis
Triggering factors in childhood psoriasis
Quality of care for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany
Global Psoriasis Atlas – Work Stream 2
Global Burden of Disease: A Systematic Literature Review on Disability Weights for Skin Diseases
Genetics
MIR-499 polymorphism is associated with susceptibility to psoriatic arthritis – preliminary study
Association between inflammasome-related polymorphisms and clinical phenotypes of Psoriatic arthritis
Health Economics and Health Policies
Frequency of Inadequate Response to Treatment among Psoriasis Patients on First-Line Biologics
Barriers of guideline-compliant care for psoriasis in Germany – Results of the European study PsoBarrier
Interesting Clinical Cases
Individualised Therapy for Psoriasis - Case series
A Unique Clinical Case of Psoriatic Arthritis and Relapsing Polychondritis
Spiny follicular hyperkeratosis in a psoriasis patient treated with ustekinumab
Combination therapy of apremilast and biological product in a patient with psoriasis.
Psoriasis worst-case scenarios: A series of 3 case reports
Successful switching to biosimilar in psoriatic patient with severe drug reaction to infliximab. A case report
Safety of Apremilast in the treatment of a psoriasis patient with chronic Hepatitis B
Pathophysiology and immunobiology
IL-22 induces keratinocytes hyperproliferation in psoriasis via miR-21 and miR-31 upregulation
Serum concentra cion of IFN-gamma in patients with psoriasis: correlation with clinical type and severity of disease
Immunological memory exists in the recurrent lesion and nonrecurrent skin after remission in psoriatic patients
Investigating systemic inflammation as the common link between depression, Psoriasis, and Psoriatic arthritis in US Veterans.
The Immune-phenotype of Small Plaque Psoriasis
Acta Derm Venereol 2018